Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA)

Oliver P. Guttmann\(^1\), Menelaos Pavlou\(^2\), Constantin O’Mahony\(^1\), Lorenzo Monserrat\(^3\), Aristides Anastasakis\(^4\), Claudio R apezzi\(^5\), Elena Biagini\(^5\), Juan Ramon Gimeno\(^6\), Giuseppe Limongelli\(^7\), Pablo Garcia-Pavia\(^8\), William J. McKenna\(^1\), Rumana Z. Omar\(^2,9\) and Perry M. Elliott\(^1\); for the Hypertrophic Cardiomyopathy Outcomes Investigators

\(^1\)The Inherited Cardiac Diseases Unit, The Heart Hospital/University College London, London, UK; \(^2\)Department of Statistical Science, University College London, London, UK; \(^3\)Cardiology Department and Research Unit, A Coruña University Hospital, Galician Health Service, Spain; \(^4\)Unit of Inherited Cardiovascular Diseases, 1st Department of Cardiology, University of Athens, Athens, Greece; \(^5\)Institute of Cardiology, Department of Specialised, Experimental and Diagnostic Medicine, University of Bologna, Bologna, Italy; \(^6\)Cardiac Department, University Hospital Virgen Arrixaca, Murcia-Cartagena s/n, El Palmar, Murcia, Spain; \(^7\)Monaldi Hospital, Second University of Naples, Naples, Italy; \(^8\)Heart Failure and Inherited Cardiac Diseases Unit, Hospital Universitario Puerta del Hierro Majadahonda, Madrid, Spain; and \(^9\)Biostatistics Group, University College London Hospitals/University College London Clinical Research Centre, University College London, London, UK

Received 22 March 2015; revised 14 May 2015; accepted 4 June 2015; online publish-ahead-of-print 16 July 2015

Aims

Atrial fibrillation (AF) and thrombo-embolism (TE) are associated with reduced survival in hypertrophic cardiomyopathy (HCM), but the absolute risk of TE in patients with and without AF is unclear. The primary aim of this study was to derive and validate a model for estimating the risk of TE in HCM. Exploratory analyses were performed to determine predictors of TE, the performance of the CHA2DS2-VASc score, and outcome with vitamin K antagonists (VKAs).

Methods and results

A retrospective, longitudinal cohort of seven institutions was used to develop multivariable Cox regression models fitted with pre-selected predictors. Bootstrapping was used for validation. Of 4821 HCM patients recruited between 1986 and 2008, 172 (3.6%) reached the primary endpoint of cerebrovascular accident (CVA), transient ischaemic attack (TIA), or systemic peripheral embolus within 10 years. A total of 27.5% of patients had a CHA2DS2-VASc score of 0, of whom 9.8% developed TE during follow-up. Cox regression revealed an association between TE and age, AF, the interaction between age and AF, TE prior to first evaluation, NYHA class, left atrial (LA) diameter, vascular disease, and maximal LV wall thickness. There was a curvilinear relationship between LA size and TE risk. The model predicted TE with a C-index of 0.75 [95% confidence interval (CI) 0.70–0.80] and the D-statistic was 1.30 (95% CI 1.05–1.56). VKA treatment was associated with a 54.8% (95% CI 31–97%, \(P = 0.037\)) relative risk reduction in HCM patients with AF.

Conclusions

The study shows that the risk of TE in HCM patients can be identified using a small number of simple clinical features. LA size, in particular, should be monitored closely, and the assessment and treatment of conventional vascular risk factors should be routine practice in older patients. Exploratory analyses show for the first time evidence for a reduction of TE with VKA treatment. The CHA2DS2-VASc score does not appear to correlate well with the clinical outcome in patients with HCM and should not be used to assess TE risk in this population.

Keywords

Hypertrophic cardiomyopathy • Atrial fibrillation • Thrombo-embolism

\(^\ast\)Corresponding author. The Heart Hospital, 16–18 Westmoreland Street, London W1G 8PH, UK. Tel: +44 207 573 8888, Fax: +44 207 575 8838, Email: perry.elliott@ucl.ac.uk

The copyright line for this article was changed on 18 September 2015 after original online publication.

© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Introduction

Hypertrophic cardiomyopathy (HCM) is a myocardial disorder characterized by LV hypertrophy not explained solely by abnormal loading conditions. It is inherited as an autosomal dominant trait and caused by mutations in cardiac sarcomere protein genes.\textsuperscript{1–3} Atrial fibrillation (AF) and thromboembolism (TE) are common complications of the disease and are associated with adverse clinical outcomes and reduced survival.\textsuperscript{4–9} However, HCM is a heterogeneous disorder with very variable clinical presentation, and the absolute risk of TE—and by implication the likely benefit from treatment—in individual patients with different clinical characteristics is unknown.\textsuperscript{1,10–12}

The primary aim of this study was to derive and validate a risk model for estimating the risk of TE in patients with HCM. Exploratory analyses were performed to determine clinical predictors of TE, the performance of the CHA\textsubscript{2}-DS\textsubscript{2}-VASc score,\textsuperscript{13} and the outcome of therapy with vitamin K antagonists (VKAs) in HCM patients with AF.

Methods

Study design and overview

Data from a retrospective, multicentre longitudinal cohort—the Hypertrophic Cardiomyopathy Outcome Investigators (www.HCMRisk.org)\textsuperscript{14}—were used in the development of the prognostic model.

The study conforms to the principles of the Helsinki declaration. The sponsors of this study did not have a role in study design, data collection, analysis, and interpretation. O.G., M.P., R.O., and P.E. had access to all data and final responsibility to submit the article. The authors from each centre guarantee the integrity of data from their institution. All investigators have agreed to the article as written.

Study population and participating centres

The study cohort consisted of all consecutively evaluated patients with HCM, followed at seven European centres: (i) The Heart Hospital, London, UK; (ii) A Coruna University Hospital, A Coruna, Spain; (iii) Unit of Inherited Cardiovascular diseases, 1st Department of Cardiology, University of Athens, Greece; (iv) Institute of Cardiology, University of Bologna, Italy; (v) University Hospital Virgen de la Arrixaca, Murcia, Spain; (vi) Monaldi Hospital, Second University of Naples, Italy; and (vii) Hospital Universitario Puerta del Hierro, Madrid, Spain. Some patients from this cohort are reported in other recently published studies.\textsuperscript{14–25}

Only adult patients (≥16 years of age) were studied. HCM was defined as a maximum LV wall thickness ≥15 mm unexplained solely by loading conditions\textsuperscript{1} or in accordance with published criteria for the diagnosis of disease in relatives of patients with unequivocal disease.\textsuperscript{26} Patients with known inherited metabolic diseases or syndromic causes of HCM were excluded from the study. Patients with a history of AF that had experienced TE prior to first evaluation at the centre were also excluded from the analysis.

Ethics approval

Patients at A Coruna University Hospital (Spain), 1st Department of Cardiology, University of Athens (Greece), University Hospital Virgen de la Arrixaca (Spain), and Monaldi Hospital (Italy) provided written informed consent. The data collection at The Heart Hospital (UK) and Hospital Universitario Puerta de Hierro (Spain) have been approved by the appropriate ethics committee. The ethics committee at the Institute of Cardiology at the University of Bologna (Italy) were informed, but approval was not required under local research governance arrangements.

Patient assessment and data collection

Patients were reviewed every 6–12 months or earlier if there was a change in symptoms. All patients underwent clinical assessment, pedigree analysis, physical examination, resting and ambulatory ECG, and transthoracic echocardiography. Each centre collected data independently using the same methodology.

Clinical outcomes

The primary outcome was a thrombo-embolic event defined as a composite of cerebrovascular accident (CVA), transient ischaemic attack (TIA), or systemic peripheral embolus as defined in the CHA\textsubscript{2}-DS\textsubscript{2}-VASc score.\textsuperscript{10,12} A CVA was defined as a focal neurological deficit of sudden onset as diagnosed by a neurologist, lasting >24 h and caused by ischaemia. A TIA was defined as a focal neurological deficit of sudden onset as diagnosed by a neurologist, lasting <24 h. Peripheral embolism was defined as TE outside the brain, heart, eyes, and lungs.\textsuperscript{13}

Selection of predictors and coding

Following a review of the literature completed in September 2012, predictors of TE that have been reported previously in patients with HCM were considered as candidate predictor variables.\textsuperscript{27} Clinical parameters were used as pre-specified predictors only when associated with TE in at least one published study, and were uniformly defined in all centres. In addition, predictors included in the CHA\textsubscript{2}-DS\textsubscript{2}-VASc score, and maximal LV wall thickness and peak left ventricular outflow tract (LVOT) gradient were considered for the analysis (Table 1). Clinically plausible interactions between selected variables such as age and AF and age and vascular disease were also assessed. All predictors were assessed at baseline evaluation.

Sample size

A minimum of 10 thrombo-embolic events were required per coefficient estimated by the model to ensure that the regression coefficients of the model were estimated with adequate precision.\textsuperscript{28} The 172 TE endpoints observed in this cohort over a 10-year follow-up period allow the estimation of up to 17 regression coefficients with adequate precision and were sufficient for development of the risk model.

General statistical methods

STATA (version 12) and R (version 3.0) were used for the statistical analyses. For descriptive results, variables are expressed as the mean ± standard deviation (SD), median and interquartile range (IQR),...
Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA)

or counts and percentages as appropriate. The follow-up time for each patient was calculated from the date of their first evaluation at participating centres to the date of the study endpoint, death, heart transplantation, cerebral haemorrhage, or the date of their most recent evaluation. The annual event rate was calculated by dividing the number of patients reaching the endpoint by the total follow-up period for that endpoint. The Kaplan–Meier method was used to estimate the cumulative probability for the occurrence of an outcome.

### Missing data

The characteristics of patients with missing information were compared with those of patients with complete information to investigate bias due to missing data. Logistic regression was used to identify the predictors of missingness. Data were assumed to be missing at random, and values for the missing predictors were imputed using multiple imputation techniques based on chained equations. The multiple imputation model included all predictors of missingness, the outcome, all pre-specified predictors of the risk model, and the estimate of the cumulative hazard function. Rubin’s rules were used to combine the estimates from 30 imputed data sets.

### Model development

All pre-specified predictors were candidates for inclusion in the final risk model. To account for potential non-linear relationships, we considered the addition of quadratic terms for all continuous predictors. Due to sample size issues, this was done in a pre-selection procedure where bi-variable models for each predictor and its quadratic term were fitted. Suspected interactions were also examined in a similar manner.

The model was developed based on the 172 events within the first 10 years of follow-up. Backward elimination with a 15% significance level was used to select the predictors for the final risk model. Centre was not included to allow the model to be used in patients from other centres. However, a sensitivity analysis for centre effect was performed by including centre in the model. The proportional hazards assumption required by the Cox model was investigated using Schoenfeld residuals. The risk model was developed using the entire cohort.

### Model validation

Bootstrapping was used to evaluate the performance of the model. This is the most efficient internal validation procedure as all aspects of the model development, including variable selection, are validated. Two hundred bootstrap samples were generated for each imputed data set, and the optimism-adjusted performance measures from the imputed data sets were combined using Rubin’s rules. The calibration slope was used to assess the degree of agreement between the observed and predicted hazards of TE. A value close to 1 suggests good overall agreement. Graphical comparisons of the observed and predicted TE at 5 years were performed. The C-index and D-statistic were used to measure how well the model discriminated between patients with high and low risk of TE. A value of 0.5 for the C-index indicates no discrimination, and a value equal to 1 indicates perfect discrimination. The D-statistic can be interpreted as the log hazard ratio (HR) for having TE between the low and high risk groups of patients. A model with no discriminatory ability results in a value of 0 for the D-statistic, with increasing values indicating greater separation.

---

**Table 1 Definition of pre-specified predictor variables assessed at baseline evaluation**

| Predictor variable | Definition | Coding |
|--------------------|------------|--------|
| Sex                | Male or female | Binary, male/female |
| Age                | Age at first evaluation in participating centres | Continuous, years |
| VKA                | Use of vitamin K antagonist at first evaluation | Binary, yes/no |
| AF                 | Detection of paroxysmal, permanent of persistent AF on ECG or Holter monitoring | Binary, yes/no |
| TE                 | Thrombo-embolism: CVA, TIA, peripheral embolus, as per CHA2DS2-VASc score | Binary, yes/no |
| NYHA               | NYHA class at first evaluation | Categorical, I, II and III–IV |
| LA                 | Anterior–posterior left atrial diameter determined by 2D echocardiography in the parasternal long axis–short axis plane at time of first evaluation | Continuous, mm |
| MWT                | The greatest LV wall thickness measured at the level of the mitral valve, papillary muscles, and apex in the parasternal short axis plane using 2D echocardiography at time of evaluation | Continuous, mm |
| FS                 | LV end-diastolic dimension – LV end-systolic dimension/LV end-diastolic dimension measured by M-Mode or 2D echocardiography at time of evaluation | Continuous, % |
| LVOT max           | The maximum LV outflow gradient determined at rest and with Valsalva provocation (irrespective of concurrent medical treatment) using pulsed and continuous wave Doppler from the apical three- and five-chamber views Peak outflow tract gradients were determined using the modified Bernoulli equation: gradient = 4V², where V is the peak aortic outflow velocity | Continuous, mmHg |
| Hypertension       | Diagnosis of hypertension prior to first evaluation, as per CHA2DS2-VASc score | Binary, yes/no |
| Diabetes           | Diagnosis of diabetes prior to first evaluation, as per CHA2DS2-VASc score | Binary, yes/no |
| Vascular disease   | Myocardial infarction, complex aortic plaque, and peripheral arterial disease, as per CHA2DS2-VASc score | Binary, yes/no |
| Heart failure      | Heart failure, especially moderate to severe LV systolic dysfunction, defined arbitrarily as LVEF < 40% (calculated by FS), as per CHA2DS2-VASc score | Binary, yes/no |

FS, fractional shortening; LA, left atrial size; LVOT max, maximum LV outflow gradient; MWT, axial wall thickness; TE, thrombo-embolic event; VKA, vitamin K antagonist.
and their coefficients. and the prognostic index is the sum of the products of the predictors between the 5-year risk of TE and age, vascular disease, and left atrial

Pre-specified subanalyses were performed to assess the relationship

Breakdown of AF in the whole cohort: paroxysmal 314, persistent 102, permanent 181, not specified 3.

Model presentation

The probability of TE at 5 years for an individual patient was calculated using the following equation, derived from the Cox proportional hazards model:

\[ P_{TE \text{ at } 5 \text{ years}} = 1 - S_0(t)^{exp(\text{prognostic index})} \]

where \( S_0(t) \) is the average survival probability at time \( t \) (i.e. at 5 years), and the prognostic index is the sum of the products of the predictors and their coefficients.

Calculation of the CHA2DS2-VASc score

The CHA2DS2-VASc score was calculated for a subset of patients with AF not treated with a VKA at baseline.10,12,13 The distribution of the score and number of events according to the score was determined.

Clinical outcome of anticoagulation in patients with atrial fibrillation

The incidence of TE in patients with AF who were and were not treated with anticoagulants was investigated using an intention to treat analysis. If a patient received treatment with a VKA at any time prior to the event, it was assumed that they continued on this medication for the duration of the study. The numbers of patients with and without TE that did or did not receive a VKA were compared. The absolute risk reduction (ARR) and number needed to treat (NNT) were calculated for patients in AF at an exploratory threshold of 4% risk of a thrombo-embolic event over 5 years.

Thrombo-embolic events during follow-up

During a follow-up period of 28,330.6 patient-years (median 6.0 years, IQR = 3–9.7), 172 (3.6%) patients reached the primary endpoint within 10 years from first evaluation (105 CVA, 53 TIA, and 14 peripheral emboli); and 107 (2.2%) patients within the first 5 years. The 5- and 10-year cumulative incidences were 2.9% [95% confidence interval (CI) 2.37–3.48%] and 6.4% (95% CI 5.42–7.53%), respectively. The clinical characteristics of patients with and without TE are shown in Table 2.

Relationship of patient characteristics to thrombo-embolic risk

Pre-specified subanalyses were performed to assess the relationship between the 5-year risk of TE and age, vascular disease, and left atrial (LA) size. Secondary analyses were performed in patients in sinus rhythm (SR) who experienced TE and patients with AF who did not experience TE.

Results

Baseline clinical characteristics

During the study period, 5104 patients were evaluated, of whom 197 were seen only once for baseline evaluation and were excluded from the analysis. Eighty-six patients with a history of AF and TE prior to first evaluation were excluded. The final study cohort consisted of the remaining 4821 patients, and the baseline clinical characteristics are shown in Table 2.

Table 2 Clinical characteristics at baseline of the whole cohort and in patients with and without a thrombo-embolic endpoint

| Predictor     | Whole cohort | No TE          | TE            |
|---------------|--------------|----------------|---------------|
|               | Total        | Mean (SD)/n (%)| Total         | Mean (SD)/n (%)| Total         | Mean (SD)/n (%)|
| Age           | 4817         | 48.99 (16.40)  | 4645          | 48.74 (16.39)  | 172           | 55.73 (15.40)  |
| LA            | 4627         | 43.97 (7.74)   | 4460          | 43.82 (7.68)   | 167           | 47.83 (8.37)   |
| MVT           | 4768         | 19.44 (5.15)   | 4599          | 19.42 (5.18)   | 169           | 20.05 (4.16)   |
| FS            | 4358         | 0.41 (0.10)    | 4198          | 0.41 (0.10)    | 160           | 0.40 (0.09)    |
| LVOT max      | 4168         | 31.95 (40.94)  | 4023          | 31.85 (40.96)  | 145           | 34.72 (40.46)  |
| Female        | 4820         | 1740 (36.10)   | 4648          | 1666 (35.84)   | 172           | 74 (43.02)     |
| Prior TE      | 4821         | 80 (1.66)      | 4649          | 71 (1.53)      | 172           | 9 (5.23)       |
| AF            | 4815         | 600 (12.46)    | 4643          | 552 (11.89)    | 172           | 48 (27.91)     |
| VKA           | 4818         | 443 (9.20)     | 4646          | 410 (8.82)     | 172           | 33 (19.19)     |
| NYHA II       | 4615         | 1584 (34.32)   | 4450          | 1519 (34.13)   | 165           | 65 (39.29)     |
| NYHA III, IV  | 4615         | 494 (10.70)    | 4450          | 456 (10.24)    | 165           | 38 (23.03)     |
| Vascular disease | 3588     | 89 (2.48)      | 3438          | 79 (22.98)     | 150           | 10 (6.67)      |
| Hypertension  | 4712         | 1414 (30.00)   | 4541          | 1354 (29.82)   | 171           | 60 (35.09)     |
| Diabetes      | 4020         | 293 (7.29)     | 3868          | 279 (7.21)     | 152           | 14 (9.21)      |

FS, fractional shortening; LA, left atrial size; LVOT max, maximum LV outflow gradient; MVT, axial wall thickness; SD, standard deviation; TE, thrombo-embolic event; VKA, vitamin K antagonist.

© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Table 3 Exploratory univariable and multivariable analysis for predictors of thrombo-embolism in hypertrophic cardiomyopathy

| Predictor       | Univariable analysis | Multivariable analysis |
|-----------------|----------------------|------------------------|
|                 | HR       | P-value | 95% CI | Predictor | HR       | P-value | 95% CI |
| Sex             | 1.43     | 0.02    | 1.06–1.93 | AGE       | 1.03     | <0.001  | 1.02–1.04 |
| AGE10           | 1.45     | <0.001  | 1.31–1.60 | AF        | 8.41     | <0.001  | 1.95–36.35 |
| AF              | 3        | <0.001  | 2.15–4.19 | Prior TE  | 3.63     | <0.001  | 1.81–7.29 |
| Prior TE        | 4.15     | <0.001  | 2.12–8.13 | NYHA II   | 1.25     | 0.21    | 0.88–1.78 |
| NYHA II         | 1.61     | 0.01    | 1.14–2.29 | NYHA III, IV | 2.07   | <0.001  | 1.35–3.17 |
| NYHA III, IV    | 3.66     | <0.001  | 2.44–5.48 | LAS       | 1.03     | <0.001  | 1.01–1.05 |
| LAS             | 1.36     | <0.001  | 1.24–1.48 | MWT       | 1.45     | <0.001  | 1.12–1.88 |
| MWT             | 1.01     | 0.3     | 0.99–1.04 | MWT²      | 0.99     | 0.01    | 0.99–1.00 |
| MWT²            | 0.22     | 0.08    | 0.04–1.20 | Vascular disease | 1.67   | 0.12    | 0.88–3.18 |
| EF              | 0.3      | 0.08    | 0.08–1.16 | EF        | 0.5      | 0.98    | 0.98–1.03 |
| LVEDD           | 1        | 0.8     | 0.98–1.03 | LVEDD     | 1        | 0.9     | 0.98–1.04 |
| LVESD           | 1.01     | 0.29    | 0.99–1.04 | LVOT max  | 1        | 0.09    | 1.00–1.01 |
| Hypertension    | 1.46     | 0.02    | 1.06–1.99 | Hypertension | 1.36   | 0.27    | 0.79–2.36 |
| Diabetes        | 1.36     | 0.27    | 0.79–2.36 | Diabetes  | 3.2      | <0.001  | 1.68–6.07 |
| Vascular disease| 3.2      | <0.001  | 1.68–6.07 | MWT       | 1.67     | <0.001  | 1.29–2.16 |
| MWT²            | 0.99     | <0.001  | 0.98–0.99 | MWT²      | 0.99     | 0.01    | 0.99–1.00 |
| MWT             | 0.99     | <0.001  | 0.98–0.99 | MWT²      | 0.99     | <0.001  | 0.98–0.99 |

AGE10, hazard ratio for 10-year increments; age_af, interaction between age and AF; CI, confidence interval; FS, fractional shortening; HR, hazard ratio; LAS, hazard ratio for left atrial size for 5 mm increments; LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension; LVOT max: maximum LV outflow gradient; MWT, maximal wall thickness; TE, thrombo-embolic; VKA, vitamin K antagonist.

The risk of TE in 5 years for an individual HCM patient can be calculated from the following equation:

\[ PTE\text{ at 5 years} = 1 - 0.9999874^{\text{prognostic index}} \]

where the prognostic index = 0.030417476 × age (years) + 2.129977874 × AF (yes = 1/no = 0) – 0.027069595 × age × AF + 1.288557829 × TE initial (yes = 1/no = 0) + 0.224673046 × NYHA II (yes = 1/no = 0) + 0.728180341 × NYHA class III/IV (yes = 1/no = 0) + 0.032251831 × LA diam (mm) – 0.3735254 × MWT (mm) – 0.008324216 × MWT² (mm) + 0.512492795 × Vascular disease (yes = 1/no = 0).

Missing data

Missing data per variable are described in the Supplementary material online, Table S2.

Model development

Univariable analyses are shown in Table 3. Only maximal LV wall thickness was found to have a non-linear association with TE, and so a quadratic term was included as a candidate for the final prognostic model. There were 15 predictors (16 regression coefficients) which were candidates for the final model.

Age, AF, the interaction between age and AF, TE prior to first evaluation, NYHA class II, NYHA class III and IV, LA diameter, vascular disease, maximal LV wall thickness, and (maximal LV wall thickness)² were included in the risk model. The estimates of the HRs and the corresponding CIs for the risk prediction model are shown in Table 3. There was no significant centre effect as part of a sensitivity analysis (shown in Supplementary material online, Table S3).

The C-index was 0.75 (95% CI 0.70–0.80) and the D-statistic was 0.28 (95% CI 0.28–0.38). Bootstrapping showed a good calibration slope of 0.9 (95% CI 0.87–0.93). Figure S1 in the Supplementary material online illustrates a good agreement between the observed and predicted risk at exploratory thresholds of thrombo-embolic risk at 5 years. The C-index was 0.75 (95% CI 0.70–0.80) and the D-statistic was 1.30 (95% CI 1.05–1.56), indicating good discrimination.

Comparison with conventional stroke prediction models

A total of 222 patients with complete data and AF were not treated with a VKA at baseline evaluation; of these, 61 (27.5%) had a CHA2DS2-VASc score of 0 and 19 (8.6%) had a score between 4

© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
and 6. No patient had a score of 7–9. Table S4 of the Supplementary material online presents the prevalence of TE in patients according to CHA2DS2-VASc score.

Figure 1 displays the cumulative incidence of TE according to CHA2DS2-VASc score groups and according to the 5-year risk prediction model.

**Relationship between anticoagulation and thrombo-embolism risk in patients with atrial fibrillation**

Table S5 of the Supplementary material online presents an unadjusted exploratory analysis of the prevalence of TE over 10 years in patients with AF at first evaluation that did or did not receive a VKA during the follow-up period prior to TE; 12.4% of those not receiving a VKA and 6.8% of patients of those who were receiving anticoagulation had a thrombo-embolic event. This corresponds to a relative risk reduction of 54.8% (95% CI 0.31–0.97, P = 0.037) with VKA treatment. Figure 2 displays the Kaplan–Meier curves comparing VKA and non-VKA groups. The ARR and NNT for patients in AF at an exploratory threshold of 4% risk of a thrombo-embolic event over 5 years is 13% (95% CI 2.1–24%) and 7.7, respectively. These results should be interpreted with caution as the small numbers meant that a standard multivariable model adjusting for warfarin and the rest of the predictors was not appropriate. Instead we fitted a multivariable model as a sensitivity analysis using Lasso regression, a penalized regression method suitable for data sets with few events.40 In this fully adjusted analysis, warfarin maintained its protective effect (results not shown).

We also used propensity score analysis to explore further the indication for the effect of VKA on stroke. The propensity score for each patient was calculated as the predicted probability of receiving a VKA. It is clinical practice in the participating centres to consider therapy with VKA in patients with significantly enlarged LA diameter. Indeed LA was the strongest balancing factor in the propensity score model to identify treatment allocation variables, while older age, history of diabetes, and smaller fractional shortening were also associated with higher probability of receiving a VKA. Subsequently a Cox regression model for the time to TE adjusting for VKA and the propensity score41 showed that VKA maintained its protective effect (HR 0.41; 95% CI 0.22–0.76).

**Relationship of left atrial size to risk of thrombo-embolic events**

Figure 3 shows the relationship between LA size and 5-year risk of TE. There appears to be a linear relationship up to ~45–50 mm, at which point the risk of TE rises exponentially with increasing LA diameter. In the cohort of patients in SR at first evaluation with an LA diameter >50 mm, the prevalence of a thrombo-embolic
A prospective external validation in a different cohort of patients would ideally be performed. Ethnicity may have influenced the findings. Data on this were not available in this cohort. The model includes patients who are treated with a VKA according to current guidelines. Excluding these patients would exclude high-risk patients and limit the statistical analysis.

Conclusions

The study shows that the risk of TE in patients with HCM can be identified using a smaller number of simple clinical features. LA size, in particular, should be monitored closely, and the assessment and treatment of conventional vascular risk factors should be routine practice in older patients. Exploratory analyses show for the first time evidence for a reduction of TE with VKA treatment. The CHA2DS2-VASc score does not appear to correlate well with the clinical outcome in patients with HCM and should not be used to assess TE risk in this population.
Supplementary Information

Additional Supporting Information may be found in the online version of this article.

Figure S1 Agreement between observed and predicted risk of atrial fibrillation not treated with a vitamin K antagonist at 5 years.

Table S1 Thrombo-embolic events in patients with sinus rhythm and atrial fibrillation at baseline evaluation.

Table S2 Missing data per variable.

Table S3 Thrombo-embolism risk prediction model and sensitivity analysis for centre effect.

Table S4 Prevalence of thrombo-embolism according to CHA2DS2-VASc score in hypertrophic cardiomyopathy patients with atrial fibrillation not treated with a vitamin K antagonist.

Table S5 Outcome of treatment with a vitamin K antagonist prior to an event in patients with atrial fibrillation at baseline evaluation with and without thrombo-embolism.

Table S6 Thrombo-embolic events in patients with sinus rhythm and left atrial size >45 and >50 at baseline evaluation.

Acknowledgements

Additional Hypertrophic Cardiomyopathy Outcomes investigators: Maite Tomé-Esteban, Antonis Pantazis, and Shaugan Dickie (The Inherited Cardiac Diseases Unit, The Heart Hospital/University College London, UK); Xusto Fernandez and Angela Lopez (Cardiology Department and Research Unit, A Coruña University Hospital, Galician Health Service, Spain); Vasiliki Vlagkouri (Unit of Inherited Cardiovascular Diseases, 1st Department of Cardiology, University of Athens, Greece); Antonio Romero (Cardiac Department, University Hospital Virgen Arrixaca, Murcia-Cartagena s/n, El Palmar, Murcia, Spain); Andrea Buono and Giuseppe Pacileo (Monaldi Hospital, Second University of Naples, Italy); and Maria Gallego-Delgado and Marta Cobo-Marcos (Heart Failure and Inherited Cardiac Diseases Unit, Hospital Universitario Puerta del Hierro Majadahonda, Manuel de Falla, Madrid, Spain).

Funding

This study was funded by the British Heart Foundation and by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. It was partially supported by the Red Investigación Cardiovascular from the Instituto de Salud Carlos III, Spanish Ministry of Health [grants RD12/0042/0049, RD12/0042/0066, and RD12/0042/0069].

Conflict of interest: O.P.G. received research support from the British Heart Foundation (FS/12/86/29841) and the National Institute for Health Research University College London Hospitals Biomedical Research Centre. All other authors declare no potential conflict of interest.

Authors’ contributions: OPG. designed the study, collected and interpreted the data, carried out the descriptive statistical analysis, and wrote the article. PM.E. designed the study, interpreted the data, and wrote the article. R.Z.O. was involved in study design, led the statistical aspects of the risk modelling, and wrote the article. M.P. carried out the statistical analysis. C.O.M., L.M., A.A., E.B., J.R.G., G.L., P.G.P., and C.R. collected and interpreted the data and critically reviewed the manuscript. WJ.M. was involved in the drafting of the article and revising it critically for important intellectual content. The additional investigators were involved in data collection and interpretation.

References

1. Elliott PM, Anastassakis A, Borger MA, Borggreve M, Cecchi F, Charron P, Hague AA, Lafont A, Limongelli G, Mahmodi H, McKenna WJ, Mogensen J, Nikoynanopoulos P, Nistri S, Pieger P, Pleske B, Rapezzi C, Rutten FH, Tillmanns C, Watkins H. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014;35:2733–2779.

2. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurotschi TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA Study. Circulation 1995;92:785–789.

3. Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet 2004;363:1881–1891.

4. Cecchi F, Olivotto I, Monterego A, Santoro G, Dolara A, Maron BJ. Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. J Am Coll Cardiol 1995;26:1529–1536.

5. Cecchi F, Olivotto I, Betocchi S, Rapezzi C, Conte MR, Smarda G, Zachara E, Gavazzi A, Rondorf R, Carnevali G, Porcu M, Nistri S, Gruppi R, Giampaoli S. The Italian Registry for hypertrophic cardiomyopathy: a nationwide survey. Am Heart J 2005;150:947–954.

6. Losi MA, Betocchi S, Aversa M, Lombardi R, Miranda M, D’Alessandro G, Cacace A, Tocchetti CG, Barbati G, Chiarello M. Determinants of atrial fibrillation development in patients with hypertrophic cardiomyopathy. Am J Cardiol 2004;94:959–960.

7. Maron BJ, Olivotto I, Bellone P, Conte MR, Cecchi F, Flygenring BP, Casey SA, Gohman TE, Bongianni S, Spina P. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. Am J Cardiol 2002;89:301–307.

8. Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001;104:2517–2524.

9. Maron BJ, Olivotto I, Spina P, Casey SA, Bellone P, Gohman TE, Graham KJ, Burton DA, Cecchi F. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation 2000;102:858–864.

10. Camm AJ, Kirchhof P, Lip GY, Schotten U, Saveleva I, Ernst S, Van Gelder IC, Al Atrash N, Hindricks G, Prendergast B, Heidbuchel H, Alferi O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goettee A, Gorenek B, Heldal M, Hohloser SH, Kohl PK, Le Heux JJ, Ponikowski P, Rutten FH, Vahanian A, Auricchio A, Bax J, Ceconi C, Dean V, Filippatos G, Funk-Crentzano C, Hobbs R, Kearney P, McDonagh T, Popescu BA, Reiner Z, Sechtem U, Sinres PA, Tendera M, Vardas PE, Widimsky P, Vardas PE, Agladze V, Aliot E, Balbansi T, Blomstrom-Lundqvist C, Capucci A, Crijns H, Dahlöf B, Folliguet T, Gilksen M, Goethals M, Gulle DC, Ho SY, Klautz R, Kose S, McMurray J, Perrone PP, Rakitaik P, Salvador MJ, Schalij M, Shpektor A, Sousa J, Stepinska U, Usetova H, Zamorano JL, Zupan I. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010;12:1360–1420.

11. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidoo SS, Nishiuma RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW. 2011 ACCF/AHA Guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive Summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;124:2761–2796.

12. Camm AJ, Lip GY, De CR, Saveleva I, Atar D, Hohloser SH, Hindricks G, Kirchhof P. 2012 focussed update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation—developed with the special contribution of the European Heart Rhythm Association. Europace 2012;14:1385–1413.

13. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010;137:263–272.

14. O’Mahony C, Jichi F, Pavlou M, Monsserrat L, Anastassakis A, R apezzi C, Biagnini E, Gimeno JR, Limongelli G, McKenna WJ, Omar R, Elliott PM. Hypertrophic Cardiomyopathy Outcomes Investigators. A novel clinical risk prediction model.
Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA)

for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD). Eur Heart J 2014;35:2010–2020.

15. O'Mahony C, Lambiase PD, Rahman SM, Cardona M, Calcagnino M, Quarta G, Tsivoskas K, Al-Shaikh S, McKenna W, Elliott P. The relation of ventricular arrhythmia electrophysiological characteristics to cardiac phenotype and circadian patterns in hypertrophic cardiomyopathy. Europace 2012;14:724 – 733.

16. O'Mahony C, Tome-Esteban M, Lambiase PD, Pantazis A, Dickie S, McKenna WJ, Elliott PM. A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy. Heart 2013;99:534 – 541.

17. Barriales-Villa R, Centurion-Inda R, Fernandez-Fernandez X, Ortiz MF, Perez-Alvarez L, Rodriguez G I, Monserrat L, Sabater R, Castro-Beiras A, Valdes M. Insights into genotype–phenotype correlation in hypertrophic cardiomyopathy. Eur J Heart Fail 2012;14:581–590.

18. Di SG, Pacileo G, Limongelli G, Baldini L, Rea A, Verrengia M, D’Andrea A, Russo MG, Calabro R. Non sustained ventricular tachycardia in hypertrophic cardiomyopathy and new ultrasonic derived parameters. J Am Soc Echocardiogr 2010;23:177–183.

19. Oliva-Sandoval MJ, Ruiz-Espejo F, Monserrat L, Hermida-Prieto M, Sabater M, Garcia-Molina E, Ortiz M, Rodriguez-Garcia MI, Nunez L, Gimeno JR, Castro-Beiras A, Valdes M. Insights into genotype–phenotype correlation in hypertrophic cardiomyopathy. Findings from 18 Spanish families with a single mutation in MYBPC3. Heart 2010;96:1980 – 1984.

20. Monserrat L, Lopez B, Gonzalez A, Hermida M, Gonzalez X, Ortiz M, Barriales-Villa R, Castro-Beiras A, Diez J. Cardiophrin-1 plasma levels are associated with the severity of hypertrophy in hypertrophic cardiomyopathy. Eur Heart J 2011;32:177–183.

21. Pacileo G, Baldini L, Limongelli G, Di SG, Iaconino M, Capogrosso C, Rea A, D’Andrea A, Russo MG, Calabro R. Prolonged left ventricular twist in cardiomyopathies: a potential link between systolic and diastolic dysfunction. Eur J Echocardiogr 2011;12:841 – 849.

22. O’Mahony C, Lambiase PD, Quarta G, Cardona M, Calcagnino M, Tsivoskas K, Al-Shaikh S, Rahman SM, Arnous S, Jones S, McKenna W, Elliott P. The long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy. Heart 2012;98:116–125.

23. Petero J, Bouzas-Mosquera A, Fernandez X, Monserrat L, Pazos P, Estevéz-Loureiro R, Castro-Beiras A. Prognostic value of exercise echocardiography in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2012;25:182–189.

24. Biagini E, Lorenzini M, Olivotto I, Rocchi G, Lovato L, Lai F, Rosmini S, Pazzi C, Pasquale F, Reggiani ML, Fattori R, Rapezzi C. Effects of myocardial fibrosis assessed by MRI on dynamic left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy: a retrospective database analysis. BMJ Open 2012;2:e001267.

25. Garcia-Pavia P, Vazquez ME, Segovia J, Salas C, Avellana P, Gomez-Bueno M, Vilches C, Gallardo ME, Garesse R, Molano J, Bornstein B, Alonso-Pulpon L. Genetic basis of end-stage hypertrophic cardiomyopathy. Eur J Heart Fail 2011;13:1193 – 1201.

26. McKenna WJ, Spirito P, Deans M, Dubourg O, Komajda M. Experience from clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families. Heart 1997;77:130–132.